Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

(2014) M. Hie et al.   BLOOD

Syndromes of Thrombotic Microangiopathy

(2014) James N. George et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of plasma exchange on rituximab pharmacokinetics

(2013) Nicolas Azzopardi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease

(2013) Florent Puisset et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: Report of four cases

(2013) Myrna Pequeño-Luévano et al.   Hematology

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center

(2012) Rodrigo Cartin-Ceba et al.   ARTHRITIS AND RHEUMATISM

Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies

(2012) W. Barcellini et al.   BLOOD

Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

(2012) Marie Scully et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse

(2012) J-P. Westwood et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura

(2012) Paul Coppo et al.   PRESSE MEDICALE

A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura

(2011) M. Scully et al.   BLOOD

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

(2011) Antoine Froissart et al.   CRITICAL CARE MEDICINE

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias

(2010) D. Gomez-Almaguer et al.   BLOOD

Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)

(2010) H. B. Feys et al.   BLOOD

Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

(2010) E. P. Rhee et al.   Clinical Journal of the American Society of Nephrology

Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura

(2010) V. MCDONALD et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience

(2010) Paul Coppo et al.   PLoS One

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis

(2009) Rachel B. Jones et al.   ARTHRITIS AND RHEUMATISM

Survival and relapse in patients with thrombotic thrombocytopenic purpura

(2009) J. A. K. Hovinga et al.   BLOOD

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

(2008) F. Zaja et al.   HAEMATOLOGICA